Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Lattice models (e.g. BIO-LGCA models) Models similar to Dissipative particle dynamics that solve Newton's equation of motion with dissipative and random forces Models where cells depict Voronoi regions and an effective potential (based on Voronoi graphs) for the tissue is used Continuum models, e.g. with the use of a phase field Kinetic theories similar to the Boltzmann equation These mathematical models give some insight in complex phenomena like cancer, wound healing and ectoplasms.
==== Robust transport networks ==== According to FAO, robust transport networks can prevent or limit increases in travel time – and consequent impacts on food costs – when an adverse event limits or prevents access to critical network links. For example, flooding, whether from flash floods or from longer-term stagnant flooding, reduces the connectivity of any transport network, impacting the movement of people, goods and societal functioning in general. Damage from flooding can indirectly affect larger areas for a longer period of time, such as when there are traffic delays and congestion on alternative routes, increased journey distances/durations, increased fuel consumption and associated greenhouse gas (GHG) emissions. Due to climate change, transport networks are increasingly being exposed to extreme weather events. A study on the transport networks of 90 countries finds that where food is transported more locally and where the network is denser – such as in high-income countries and densely populated countries like China, India, Nigeria and Pakistan –, systematic disturbances have a much lower impact. Conversely, low-income countries have much lower levels of transport network resilience, although some exceptions exist. The study further simulates the effect of potential disruptions – namely floods – to food transport networks which illustrate that the loss of network connectivity that results when links become impassable potentially affects millions of people.
==== Translation ==== Two different sets of proteins are translated from viral mRNAs. The first set is represented by six structural proteins that include nucleocapsid protein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), neuraminidase (NA) and large protein (L). All these proteins have variable functions and are incorporated into the viral capsid (see the section "Virion structure" above). The second set is represented by seven non structural or accessory proteins. These proteins are translated from the polycistronic mRNA of P gene. This mRNA encodes eight translation products, and P-protein is only one of them. Alternative variants of translation are represented by V, W, C, C′, Y, Y′ and X proteins. The proteins C′, C, Y1, Y2 are products of mRNA alternative reading frame, they collectively referred as C-proteins or C-nested proteins and they share common C-terminal end. The X protein also shares the same C-terminal end and its translation also independently initiated by ribosomes. The proteins V and W are products of cotranscriptional mRNA editing. All these non-structural proteins have multiple functions, including the organization of viral RNA synthesis and helping the virus to infect host cells by escaping host innate immunity (see "Virus-induced immunosuppression" section above).
Sources: en.wikipedia.org
Corneal opacification is a term used when the cornea of the eye loses its transparency. The term corneal opacity is used particularly for the loss of transparency of cornea due to scarring. Transparency of the cornea is dependent on the uniform diameter and the regular spacing and arrangement of the collagen fibrils within the stroma. Alterations in the spacing of collagen fibrils in a variety of conditions including corneal edema, scars, and macular corneal dystrophy is clinically manifested as corneal opacity. The term corneal blindness is commonly used to describe blindness due to corneal opacity. Keratoplasty also known as corneal transplantation is the main treatment option for visual improvement in corneal opacity. Other treatments which may improve visual outcome includes optical iridectomy, phototherapeutic keratectomy and keratoprosthesises. Corneal tattooing may be used for improving the cosmetic appearance of the opaque eye.
=== Other adverse reactions === Adverse reactions may result from the poor quality of kava raw material used in the manufacturing of various kava products. Other adverse reactions from chronic use may include visual impairment, rashes or dermatitis, seizures, weight loss, and malnutrition, although there is limited high-quality research on these possible effects.
=== Paleomagnetic dating === A sequence of paleomagnetic poles (usually called virtual geomagnetic poles), which are already well defined in age, constitutes an apparent polar wander path (APWP). Such a path is constructed for a large continental block. APWPs for different continents can be used as a reference for newly obtained poles for the rocks with unknown age. For paleomagnetic dating, it is suggested to use the APWP in order to date a pole obtained from rocks or sediments of unknown age by linking the paleopole to the nearest point on the APWP. Two methods of paleomagnetic dating have been suggested: (1) the angular method and (2) the rotation method. The first method is used for paleomagnetic dating of rocks inside of the same continental block. The second method is used for the folded areas where tectonic rotations are possible.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.